Prescribed computer games in addition to occlusion versus standard occlusion treatment for childhood amblyopia: a pilot randomised controlled trial

Table 3 BCVA and stereoacuity at 6 and 12 weeks

Visual outcomes	Standard (n = 20) Median (IQR)			Eye 5 (n = 19) Median (IQR)			Nintendo(n = 19) Median (IQR)
Baseline BCV	Severe	Moderate	None	Severe	Moderate	None	Severe	Moderate	None
Amblyopic or non-amblyopic eyes	n = 9	n = 11	n = 20	n = 5	n = 13	n = 19	n = 6	n = 13	n = 18
Amblyopic or non-amblyopic eyes	0.8 (0.8–1)	0.36 (0.32–0.5)	0.1 (0.01–0.12)	0.76 (0.7–0.78)	0.35 (0.3–0.5)	0.1 (0.05–0.14)	0.8 (0.7–0.9)	0.4 (0.32–0.46)	0.1 (0.02–0.12)
6 weeks VA	Severe	Moderate	None	Severe	Moderate	None	Severe	Moderate	None
Amblyopic or non-amblyopic eyes	n = 8	n = 11	n = 19	n = 5	n = 12	n = 17	n = 5	n = 12	n = 17
Amblyopic or non-amblyopic eyes	0.6 (0.59–0.89)	0.22 (0.06–0.4)	0.1 (0–0.15)	0.62 (0.58–0.75)	0.25 (0.19–0.31)	0.06 (0.05–0.12)	0.5 (0.5–0.7)	0.25 (0.2–0.38)	0.1 (0–0.1)
12 weeks VA	Severe	Moderate	None	Severe	Moderate	None	Severe	Moderate	None
Amblyopic or non-amblyopic eyes	n = 8	n = 10	n = 18	n = 4	n = 11	n = 15	n = 6	n = 12	n = 18
Amblyopic or non-amblyopic eyes	0.53 (0.47–0.73)	0.28 (0.12–0.4)	0.1 (0–0.14)	0.5 (0.46–0.59)	0.15 (0.1–0.2)	0.06 (0.02–0.1)	0.54 (0.5–0.58)	0.14 (0.1–0.31)	0.01 (0–0.1)
Stereopsis
Baseline	0 (0–155)			110 (0–170)			110 (0–480)
6 weeks	0 (0–170), N = 19			85 (0–170), N = 16			110 (70–170), N = 17
12 weeks	0 (0–100), N = 18			85 (0–100), N = 14			85 (0–110), N = 18

N = total number of patients in the study arm, n = number of patients in the group with valid data (only shown when there is invalid or missing data); At 12 weeks, median BCVA in children with severe amblyopia in the standard advice group improved by 0.27, in the Eye Five group by 0.26 logMar and in the Nintendo group by 0.26 logMar. In children with moderate amblyopia, median BCVA improved by 0.08, 0.2 and 0.26 logMar, respectively. Change in stereoacuity was small, if any
IQR interquartile range

ISSN: 2055-5784